Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease. Patients will be included in cohort #1 or cohort #2. The inclusion in cohort #2 will start when the results of the cohort #1 are available. Patient will receive either cetuximab alone (cohort #1) or cetuximab with irinotecan (cohort #2).


Clinical Trial Description

Background - Rationale KRAS and NRAS mutations are present in roughly 50% of patients with advanced colorectal cancer and predict failure of anti-EGFR mabs therapies, thus genotyping colorectal cancer (CRC) is mandatory for personalized treatments. Research has been selectively concentrated on the emergence of resistant clones in the blood of patients with wild-type (WT) RAS CRC as biomarker of anti-EGFR therapy resistance. It has been suggested that patients with metastatic CRC harboring mutated primary tumors, thus not candidate to EGFR inhibitors, frequently have WT RAS circulating tumor cells in blood. Preliminary data suggest that patients with mutant KRAS colon cancer can frequently (50%) switch to a prevalent WT KRAS disease in course of treatment with anti-angiogenic drugs. In patients with RAS wild-type colorectal cancer who previously received standard therapies, anti-EGFR mabs achieve a response rate of 20% as monotherapy and 30-40% in combination with irinotecan. The aim of this study is to evaluate the efficacy of cetuximab in patients with pretreated neo wild-type colorectal cancer using liquid biopsies for RAS molecular assessment Study Objectives Primary: • To evaluate the response rate using RECIST 1.1 Secondary: - To evaluate progression-free survival (PFS), overall survival (OS) - To evaluate disease control rate (DCR) - To evaluate safety Exploratory: - Frequency of neo wild-type tumors - Frequency of RAS and BRAF neomutations during treatment Study Design Prospective multicentric single-arm open-label phase II study in to 2 successive patient cohorts (cohort #1 followed by cohort #2). Molecular screening using Idylla™ (Biocartis) ctKRAS and ctNRAS/BRAF Mutation Assays. Cohort #1: Patients will be treated with cetuximab monotherapy (cetuximab 500mg/m² IV, day 1). Cohort #2: Patients will be treated with cetuximab and irinotecan (cetuximab 500mg/m² IV, day 1; irinotecan 180mg/m² IV, day 1). In both cohorts, treatment will be given intravenously every 14 days (q2w) until disease progression or limiting toxicity. Tumor evaluations will be done with CT-scan (or MRI) every 8 weeks using RECIST v1.1. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04189055
Study type Interventional
Source GCS IHFB Cognacq-Jay
Contact Benoist CHIBAUDEL, MD
Phone 0147595965
Email benoist.chibaudel@ihfb.org
Status Recruiting
Phase Phase 2
Start date January 7, 2020
Completion date July 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05536089 - ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation
Active, not recruiting NCT04392479 - TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study. Phase 3
Not yet recruiting NCT05577143 - Blood Screening for Adult Colorectal Cancer
Active, not recruiting NCT05585866 - Propofol and Sevoflurane Anesthesia in Colorectal Cancer Surgery: Incidence of Acute Kidney Injury
Recruiting NCT05573022 - Impact of a Patient Decision Aid Intervention N/A
Completed NCT02931825 - Identification of High Risk People for Colorectal Cancer and Evaluation of a Specific Surveillance System N/A
Recruiting NCT03301493 - Genomic Testing and Resulting Medical Decisions
Not yet recruiting NCT06324409 - ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening N/A
Not yet recruiting NCT05791747 - Representations, Beliefs and Attitudes Towards Hypnosis in Patients Followed for Colorectal Cancer
Recruiting NCT05830097 - A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT04258813 - Onco-primary Care Networking to Support TEAM-based Care N/A
Recruiting NCT05939440 - Interventions to Decrease Financial Toxicity N/A
Completed NCT04548765 - Evaluation of Letters Promoting Colorectal Cancer Testing N/A
Recruiting NCT04592003 - French Colorectal ESD Cohort in Experts Centers
Withdrawn NCT04345952 - Calm for Cancer Patients Receiving Chemotherapy N/A
Completed NCT04280393 - Effectiveness and Safety of the Colonoscopy Assisted by Endocuff vs. Standard in the Colorectal Cancer Screening N/A
Not yet recruiting NCT06231576 - Digital Home-Based Prehabilitation Before Surgery N/A
Recruiting NCT04874883 - Effect of the Use of Symbiotics in Patients With Colon Cancer Phase 4
Completed NCT04074460 - Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study Phase 4
Not yet recruiting NCT06191185 - IMProving Adherence to Colonoscopy Through Teams and Technology N/A